Clinical Guides
Cushing's Syndrome
A source-grounded endocrine guide to separating exogenous from endogenous Cushing's syndrome, testing without shortcuts, localising the cause and coordinating definitive and long-term care in India, prepared for specialist review.
MedNext Academy | 14 min read
Cushing's Syndrome
A source-grounded endocrine guide to separating exogenous from endogenous Cushing's syndrome, testing without shortcuts, localising the cause and coordinating definitive and long-term care in India, prepared for specialist review.
Summary
Cushing's syndrome describes the clinical and biochemical consequences of prolonged excessive glucocorticoid action. The commonest cause is exogenous exposure from prescribed, injected, inhaled, topical or unregulated steroid-containing products. Endogenous disease is much rarer and results from autonomous cortisol production by an adrenal lesion or ACTH-driven secretion from a pituitary corticotroph tumour, termed Cushing disease, or an ectopic source. These categories cannot be managed interchangeably. Abruptly stopping exogenous glucocorticoid can provoke adrenal insufficiency, while tumour imaging before biochemical confirmation can misdirect care toward incidental lesions.
Progressive proximal weakness, easy bruising, wide violaceous striae, facial plethora, unexplained osteoporosis, hypokalaemia, early hypertension or diabetes, and in children falling height velocity with weight gain raise suspicion more than obesity alone. First obtain a complete glucocorticoid history. If endogenous hypercortisolism remains plausible, select an appropriate first-line test: repeated 24-hour urinary free cortisol, repeated late-night salivary cortisol, or a low-dose dexamethasone suppression test. Confounders, collection quality and assay method matter; random cortisol and ACTH are not screening tests.
After concordant biochemical confirmation, ACTH guides cause-directed localisation. Treatment usually targets the causal tumour through an experienced multidisciplinary team. Severe cortisol excess, infection, thrombosis, diabetes, hypertension, hypokalaemia and psychiatric illness need parallel management. Surgery may produce temporary or permanent adrenal insufficiency, requiring replacement and education. Medical therapy, radiotherapy and bilateral adrenalectomy have defined roles but substantial trade-offs. Evidence is strongest for specialist pathways, not self-directed screening or treatment from a symptom list.
How Common Is It?
Exogenous Cushing's syndrome is far more common than endogenous disease because glucocorticoids are used across respiratory, rheumatological, dermatological, neurological, oncology and transplant care. Exposure is not limited to oral tablets. Repeated depot injections, potent skin preparations over large areas, inhaled or intranasal treatment at high exposure, ocular formulations and unlabelled traditional or bodybuilding products can contribute, particularly with interacting medicines that slow steroid metabolism. The probability depends on potency, dose, duration, route, absorption, co-medication and individual susceptibility; no single threshold predicts every patient.
Endogenous Cushing's syndrome is rare. Among confirmed endogenous cases, pituitary ACTH secretion is the commonest cause, followed by adrenal cortisol production and ectopic ACTH secretion, but proportions vary by age and referral population. Specialist-centre series overestimate complexity and cannot provide community prevalence. Many common features such as obesity, depression, hypertension, diabetes, menstrual irregularity and fatigue have low specificity. Widespread screening of everyone with one such feature creates false positives and harm.
Testing is more appropriate when several progressive features accumulate, when manifestations are unusual for age, when a child gains weight while linear growth slows, or when an adrenal incidentaloma has features requiring cortisol assessment. Cyclical disease may alternate between abnormal and normal secretion, making prevalence and diagnosis particularly difficult. No reliable contemporary Indian population incidence is asserted here. Underdiagnosis, delayed referral, assay availability and unrecorded steroid exposure probably influence observed burden. The practical goal is selective case finding with a disciplined pathway, not turning a rare endogenous disorder into a generic explanation for weight gain.
Risk Factors
The major risk for exogenous disease is sustained supraphysiological glucocorticoid exposure. Ask about every route and indication, duration, recent dose changes and products obtained without a prescription. Potent topical steroids used on inflamed or occluded skin, repeated intra-articular or intramuscular injections, and concurrent CYP3A4 inhibitors can increase systemic exposure. Children may be particularly vulnerable to growth suppression. A person with cushingoid appearance during current or recent glucocorticoid treatment should also be considered at risk of hypothalamic-pituitary-adrenal suppression; apparent cortisol excess does not protect against crisis when the medicine is stopped or physiological stress occurs.
No routine lifestyle profile predicts a pituitary, adrenal or ectopic tumour. Certain inherited syndromes increase risk of specific endocrine tumours, but genetic evaluation is specialist-led and guided by age, family history and tumour pattern. Smoking history matters after ACTH-dependent disease is confirmed because some ectopic sources arise from thoracic neuroendocrine or other malignancies, not because smoking alone justifies cortisol screening. Adrenal incidentaloma prompts an endocrine assessment according to lesion and patient context rather than automatic attribution of every symptom.
Risk of harm after disease develops is substantial. Severe hypercortisolism predisposes to infection, venous thromboembolism, hypertension, diabetes, hypokalaemia, osteoporosis, fractures, muscle wasting, poor wound healing, psychiatric disturbance and cardiovascular events. Pregnancy and childhood require specialist approaches. Diagnostic risk also matters: depression, alcohol-use disorder, severe obesity, poorly controlled diabetes, obstructive sleep apnoea, acute illness, pain and disrupted sleep can produce non-neoplastic hypercortisolism or false-positive tests. Oral oestrogen, renal impairment and medicines affecting dexamethasone metabolism can alter particular assays. Identifying these factors before testing is part of safe practice, not a reason to dismiss convincing progressive signs.
Diagnosis
Diagnosis is stepwise: establish whether exposure is exogenous, demonstrate endogenous cortisol excess with appropriate repeat testing, then determine its cause. Test selection and interpretation should be supervised by endocrinology when suspicion is meaningful or any result is abnormal.
History
Document progressive change with dates, photographs or growth records where appropriate. Ask bruising, skin thinning, wide striae, proximal weakness, fractures, infections, mood or cognitive change, sleep, menstrual and sexual function, fertility, headache, visual symptoms, kidney stones, hypertension and diabetes. In children plot weight and height velocity. Take an exhaustive drug history covering oral, injected, inhaled, nasal, eye, skin and unregulated products, plus medicines that alter steroid metabolism. Ask alcohol intake, depression, shift work, pregnancy possibility, renal disease and collection constraints that could confound testing.
Examination
Record blood pressure, weight trajectory, fat distribution, facial plethora, supraclavicular fullness, skin thickness, ecchymoses, striae colour and width, acne, hirsutism, oedema and infection. Test proximal power functionally and look for vertebral tenderness or fracture. Assess pigmentation, visual fields and tumour clues without assuming phenotype identifies cause. Examine children for pubertal and linear-growth effects.
Investigations
Suitable initial tests are at least two urinary free cortisol collections, two late-night salivary cortisol samples, a 1-mg overnight dexamethasone suppression test or, in selected settings, a 48-hour low-dose test. Use assay-specific ranges and verify collection and dexamethasone confounders. Random serum cortisol, random ACTH, imaging and high-dose dexamethasone are not screening tests. One abnormal result generally requires endocrinology review and another recommended test. Concordant positive results, after excluding non-neoplastic hypercortisolism, permit cause evaluation; discordant or cyclical patterns need longitudinal specialist assessment.
Differential Diagnosis
Exogenous Cushing's syndrome must be separated first because management focuses on the indication for steroid, a safe taper when the underlying disease permits, and adrenal-insufficiency precautions. Stopping abruptly can be dangerous. Products may be hidden in combination creams, injections or supplements, so a negative answer to 'Do you take steroid tablets?' is inadequate. Physiological replacement for established adrenal insufficiency can also appear excessive if dosing is too high, but reducing it requires its own endocrine plan.
Non-neoplastic hypercortisolism, historically called pseudo-Cushing states, can accompany major depression, alcohol-use disorder, severe obesity, poorly controlled diabetes, obstructive sleep apnoea, intense physiological stress or malnutrition. These conditions may disrupt circadian cortisol or dexamethasone suppression. They can coexist with true Cushing's syndrome; clinical progression and repeat specialist testing after treating reversible factors are more reliable than dismissing an abnormal result. Pregnancy changes cortisol-binding globulin and normal cortisol physiology. Shift work undermines late-night sampling, renal impairment can reduce urinary cortisol reliability, and oral oestrogen may cause false-positive serum dexamethasone tests.
Phenotypic alternatives include polycystic ovary syndrome, metabolic syndrome, simple obesity, familial lipodystrophy, glucocorticoid resistance and other causes of proximal weakness or osteoporosis. After endogenous excess is confirmed, low or suppressed ACTH suggests ACTH-independent adrenal disease; normal or high ACTH suggests pituitary or ectopic secretion. Pituitary incidentalomas are common enough that MRI alone cannot prove Cushing disease. Rapid severe illness, profound hypokalaemia, marked hypercortisolism, weight loss or a tumour syndrome can favour ectopic ACTH but is not diagnostic. Inferior petrosal sinus sampling is a specialised localisation procedure, not a test for whether hypercortisolism exists.
Management
For exogenous disease, the prescribing team and endocrinology should balance control of the original illness against steroid toxicity. Reduce only when the underlying condition allows, use the lowest effective exposure and follow a taper or adrenal-recovery strategy appropriate to duration and dose. Educate about adrenal crisis risk during illness, procedures or vomiting. Removing an undisclosed steroid product needs the same caution. Treat osteoporosis risk, diabetes, hypertension, infection and psychological effects rather than waiting for the appearance to resolve.
For confirmed endogenous disease, first-line treatment is generally removal of the causal tumour by an experienced surgeon: transsphenoidal surgery for pituitary disease, adrenalectomy for a unilateral adrenal source and tumour-directed treatment for ectopic ACTH where feasible. Preoperative preparation is individualised. Severe cortisol excess may require medical control before surgery, with active treatment of hypokalaemia, hyperglycaemia, hypertension, infection and thrombotic risk. Multidisciplinary planning should include endocrinology, the relevant surgeon, anaesthesia, radiology, pathology and other specialties.
Persistent or recurrent disease may be treated with repeat surgery, radiotherapy, cortisol-lowering medicine, pituitary-directed medicine, glucocorticoid-receptor blockade or bilateral adrenalectomy. Choice depends on cause, urgency, tumour anatomy, fertility, comorbidity, interactions, monitoring capacity, availability, cost and patient preference. Radiotherapy has a delayed and variable effect, so biochemical control is needed while waiting and lifelong pituitary surveillance is required. Bilateral adrenalectomy provides rapid control of adrenal cortisol production but causes permanent adrenal insufficiency and, in pituitary disease, requires monitoring for corticotroph tumour progression. No treatment guarantees immediate recovery of muscle, bone, mood or cardiovascular risk; long-term follow-up remains essential.
Prescribing Information
Drug therapy for endogenous Cushing's syndrome belongs with an experienced endocrine team. Adrenal steroidogenesis inhibitors include metyrapone, osilodrostat, ketoconazole or levoketoconazole and mitotane; intravenous etomidate can be used for life-threatening hypercortisolism in monitored specialist care. These agents differ in speed, liver toxicity, electrolyte and androgen effects, interactions, pregnancy risk and the chance of precipitating adrenal insufficiency. Some clinicians titrate to biochemical targets, while severe cases may use a block-and-replace strategy. Product approval and availability vary internationally and within India, so a generic list must not be read as a local formulary.
Pituitary-directed options include pasireotide and, in selected practice, cabergoline. Mifepristone blocks the glucocorticoid receptor and can improve hyperglycaemia but makes serum cortisol unsuitable for monitoring and can worsen hypokalaemia or cause endometrial effects. None substitutes for establishing the diagnosis and cause. Ketoconazole-related hepatotoxicity, pasireotide-related hyperglycaemia, metyrapone-related mineralocorticoid or androgen effects and multi-drug interactions require planned laboratory and clinical surveillance. Women who may become pregnant need explicit counselling because pregnancy risks differ.
After successful surgery, suppressed normal corticotroph or contralateral adrenal function commonly causes hypocortisolism. The Endocrine Society recommends glucocorticoid replacement for hypocortisolaemic patients plus education about adrenal insufficiency, followed by biochemical assessment of hypothalamic-pituitary-adrenal recovery. Dose, route and perioperative regimen vary with procedure and centre. Patients need sick-day rules, an emergency plan and warning against abrupt withdrawal. Overreplacement recreates cortisol toxicity; underreplacement risks crisis. Analgesics, anticoagulation, antihypertensives, diabetes therapy, antimicrobial prophylaxis and bone medicines must be individualised rather than automatically bundled into one regimen.
When to Refer
Refer to endocrinology when progressive discriminatory features raise suspicion, when a child shows weight gain with falling height velocity, when an adrenal incidentaloma needs cortisol assessment, or when any appropriate screening test is abnormal. A high pretest probability with normal or discordant tests, suspected cyclic disease and significant test confounders also need specialist review. Do not order serial imaging to bypass endocrine evaluation. Exogenous exposure with severe toxicity, difficult tapering, uncertain adrenal reserve, pregnancy or a cushingoid patient facing surgery warrants coordinated advice even if endogenous disease is not suspected.
Confirmed endogenous hypercortisolism should be referred to a multidisciplinary centre able to perform high-quality pituitary and adrenal imaging, assay-aware testing, endocrine surgery and perioperative care. ACTH-dependent disease with a small or negative pituitary MRI may require specialised dynamic testing or inferior petrosal sinus sampling to distinguish pituitary from ectopic secretion. This invasive test should be done only in an experienced centre while hypercortisolism is biochemically present. Suspected ectopic ACTH may require coordinated thoracic, oncology, nuclear-medicine or other tumour evaluation.
Urgent admission is appropriate for severe hypokalaemia, uncontrolled hypertension or hyperglycaemia, serious infection, psychosis or suicidality, thromboembolism, heart failure, acute fracture, rapidly progressive catabolism or very high cortisol with clinical deterioration. Postoperative vomiting, hypotension, fever, confusion or inability to take replacement can signal adrenal crisis. Long-term referral remains necessary after apparent remission for recurrence surveillance, pituitary function, adrenal recovery, bone health, cardiovascular risk, mental health and quality of life. Shared care should define who orders each test and who responds to an abnormal result.
Red Flags
Severe endogenous hypercortisolism can become a medical emergency. Red flags include profound hypokalaemia, severe infection with muted inflammatory signs, uncontrolled hyperglycaemia, hypertensive crisis, venous thromboembolism or pulmonary embolism, acute heart failure, severe muscle weakness, psychosis, suicidal risk and rapidly progressive symptoms. Patients with ectopic ACTH secretion may deteriorate quickly and can lack the classic obese appearance. Admit, monitor, treat complications and obtain urgent endocrine advice; rapid cortisol control may require combination oral therapy, monitored intravenous etomidate or surgery depending on cause and capability.
Adrenal insufficiency is an equally important red flag during tapering, after tumour treatment or while taking cortisol-lowering medicine. Repeated vomiting, collapse, hypotension, severe weakness, abdominal pain, confusion, hypoglycaemia or major electrolyte disturbance requires emergency glucocorticoid and fluid assessment under the applicable adrenal-crisis protocol. Biochemical 'control' can overshoot into deficiency. Patients using glucocorticoid-receptor blockade cannot be monitored by cortisol concentration alone, so clinical deterioration demands expert interpretation.
New visual loss, ophthalmoplegia, sudden severe headache or reduced consciousness raises concern for pituitary apoplexy or mass effect and requires emergency pituitary and neurosurgical assessment. Fever, wound change or neurological decline after surgery is also urgent. A patient with confirmed Cushing's syndrome and chest pain, unilateral leg swelling, acute breathlessness or focal neurological deficit needs immediate thromboembolic or vascular evaluation. Red flags should be written into perioperative and discharge plans. The safe response is not merely to repeat a cortisol test; it is simultaneous stabilisation, complication treatment and cause-specific endocrine coordination.
Indian Clinical Context
Indian patients may encounter fragmented steroid exposure across pharmacies, multiple specialists, injections, combination skin creams and traditional or gym products. A reconciliation should record brand, active ingredient, strength, route, frequency and last use, and families can be asked to bring containers or photographs. The purpose is safety, not blame. Abrupt cessation remains dangerous when hypothalamic-pituitary-adrenal suppression is possible. Clear instructions in the patient's preferred language should distinguish reducing exogenous exposure from testing for an endogenous tumour.
Access to late-night salivary cortisol, reliable urinary free cortisol assays, dexamethasone measurement, 3T pituitary MRI and inferior petrosal sinus sampling is uneven. Laboratories may use different immunoassays or mass-spectrometry methods and reference ranges. Referral samples, transport and collection timing can create error. A sensible pathway uses locally validated tests, repeats discordant results and refers before expensive imaging. If pituitary sampling or expert endocrine surgery is unavailable locally, early centre-to-centre coordination is safer than sequential empirical treatment.
Medicine licensing, supply and affordability differ from North American and European guidelines. Do not promise access to osilodrostat, pasireotide, mifepristone or other specialist agents. Ketoconazole and metyrapone also require monitoring and interaction review; acquiring a drug is not equivalent to having a safe programme. Surgical volume and pathology expertise matter, particularly for small corticotroph tumours. National undergraduate curriculum supports recognition and referral but does not create a single national Cushing treatment protocol. A realistic plan includes travel, cost, laboratory follow-up, emergency steroid access after surgery and communication between endocrine, surgical and primary teams. Teleconsultation can support continuity but cannot replace examination or emergency care for severe complications.
NMC Competency Mapping
Cushing's syndrome links hypothalamic-pituitary-adrenal physiology, steroid pharmacology, pituitary and adrenal pathology, internal medicine, paediatrics, surgery and communication in the NMC Competency Based Medical Education Curriculum 2024. The learner should explain normal circadian cortisol control, negative feedback and ACTH-dependent versus ACTH-independent excess. They should recognise that prescribed glucocorticoid is the commonest cause and that exogenous cushingoid appearance can coexist with adrenal suppression. A complete multi-route medicine history is therefore a core clinical skill, not an optional preliminary question.
At the 'know how' level, learners should identify progressive discriminatory features, plot height and weight in children, select conceptually appropriate screening tests and explain why random cortisol, ACTH and imaging are unsuitable for screening. They should describe common confounders and the sequence from biochemical confirmation to ACTH measurement and cause-directed localisation. Clinical reasoning includes separating pituitary Cushing disease from ectopic ACTH and adrenal causes without claiming that one MRI lesion proves origin.
Supervised practice may include counselling on specimen collection, presenting a structured endocrine referral, identifying severe infection, hypokalaemia or thrombosis, and explaining postoperative adrenal-replacement precautions with teach-back. Learners should understand tumour-directed surgery, broad categories of medical therapy, delayed radiotherapy effect and permanent consequences of bilateral adrenalectomy. Curriculum mapping does not authorise independent dexamethasone testing, steroid tapering, specialist prescribing or localisation procedures. Competence includes knowing when assay limitations, medicine access, pregnancy, childhood or rapid deterioration require expert escalation.
Key Exam Pearls for NEET PG
Cushing's syndrome means cortisol effect from any cause; Cushing disease specifically means an ACTH-secreting pituitary corticotroph tumour. Exogenous glucocorticoid exposure is the commonest overall cause and typically suppresses ACTH and endogenous adrenal function. Never stop chronic glucocorticoid abruptly. Among endogenous causes, ACTH-dependent disease includes pituitary and ectopic secretion, while ACTH-independent disease is usually adrenal. First confirm endogenous hypercortisolism, then use ACTH and cause-directed imaging; imaging is not a screening test.
High-yield discriminatory features include proximal myopathy, easy bruising, facial plethora, wide violaceous striae, osteoporosis unusual for age and, in children, increasing weight with falling height velocity. Initial tests are repeated urinary free cortisol, repeated late-night salivary cortisol, 1-mg overnight dexamethasone suppression or a selected low-dose 48-hour test. Random serum cortisol and ACTH are inappropriate screens. Oral oestrogen can confound serum dexamethasone testing, renal impairment affects urinary cortisol, shift work disrupts late-night sampling and depression, alcohol-use disorder, severe obesity or uncontrolled diabetes can mimic biochemical excess.
Pituitary MRI may be negative because corticotroph tumours are small and may reveal an incidental lesion. Inferior petrosal sinus sampling distinguishes pituitary from ectopic ACTH in selected confirmed ACTH-dependent cases; it does not diagnose cortisol excess. First-line endogenous treatment is usually causal tumour resection. After successful surgery, glucocorticoid replacement may be required until axis recovery. Persistent disease options include repeat surgery, radiation, steroidogenesis inhibitors, pituitary-directed drugs, receptor blockade or bilateral adrenalectomy. Bilateral adrenalectomy causes permanent adrenal insufficiency and in Cushing disease requires surveillance for corticotroph tumour progression.
Frequently Asked Questions
Can a person have Cushing's appearance and still be at risk of adrenal crisis?
Yes. Exogenous glucocorticoids can produce cushingoid features while suppressing the body's own ACTH and cortisol production. Abrupt withdrawal, vomiting, major illness or surgery may then expose adrenal insufficiency. The medicine should be reconciled and tapered only when the underlying disease permits, with stress-dose and emergency advice based on current exposure and recovery, not on appearance alone.
Why is a random morning cortisol not enough to diagnose Cushing's syndrome?
Cortisol varies with time, sleep, stress, binding proteins, illness and assay. Cushing screening tests examine different abnormalities: loss of the late-night nadir, failure to suppress after dexamethasone or increased integrated urinary free cortisol. Appropriate tests usually need repeat samples and confounder review. Random cortisol and ACTH neither reliably establish endogenous excess nor identify its source.
Does a pituitary lesion on MRI prove that ACTH-dependent Cushing's syndrome is Cushing disease?
No. Small incidental pituitary lesions occur in people without Cushing disease, while genuine corticotroph tumours can be too small for routine MRI. After endogenous cortisol excess and ACTH dependence are established, imaging is interpreted with biochemical evidence. Equivocal cases may need specialist dynamic testing or inferior petrosal sinus sampling in an experienced centre while the patient is hypercortisolaemic.
Why might glucocorticoid replacement be needed after apparently successful surgery?
Chronic cortisol excess suppresses normal corticotroph and adrenal function. Removing the causal pituitary or adrenal tumour can therefore leave temporary, and sometimes permanent, hypocortisolism. Replacement protects the patient while recovery is assessed. They need sick-day rules and emergency guidance, and later biochemical testing to decide when tapering is safe; continuing excessive replacement can recreate Cushing-related harm.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic